Downregulation of β4GalT5 may promote the expression of cell surface integrin β1 and subsequently inhibit glioma malignant phenotype, and may enhance the therapeutic efficiency of As2O3 (24,25). This evidence concerns the gene B4GALT5 and central nervous system cancer.